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Abstract. Tardive dyskinesia (Td) is a serious side effect of 
certain antipsychotic medications that are used to treat schizo-
phrenia (ScZ) and other mental illnesses. The methylation 
status of the insulin receptor substrate 1 (IRS1) gene is report-
edly associated with ScZ; however, no study, to the best of 
the authors' knowledge, has focused on the quantitative dna 
methylation levels of the IRS1 gene using pyrosequencing in 
ScZ with or without Td. The present study aimed to quantify 
dna methylation levels of 4 cpG sites in the IRS1 gene using 
a chinese sample including ScZ patients with Td and without 
Td (nTd) and healthy controls (Hcs). The general linear 
model (GlM) was used to detect dna methylation levels 
among the 3 proposed groups (Td vs. nTd vs. Hc). Mean 
dna methylation levels of 4 cpG sites demonstrated normal 
distribution. Pearson's correlation analysis did not reveal any 
significant correlations between the DNA methylation levels 
of the 4 cpG sites and the severity of ScZ. GlM revealed 
significant differences between the 3 groups for CpG site 1 
and the average of the 4 cpG sites (P=0.0001 and P=0.0126, 
respectively). Furthermore, the Td, nTd and Td + nTd 
groups demonstrated lower methylation levels in cpG site 1 
(P=0.0003, P<0.0001 and P<0.0001, respectively) and the 
average of 4 cpG sites (P=0.0176, P=0.0063 and P=0.003, 
respectively) compared with the Hc group. The results 
revealed that both nTd and Td patients had significantly 
decreased dna methylation levels compared with healthy 
controls, which indicated a significant association between the 
dna methylation levels of the IRS1 gene with ScZ and Td. 
Introduction
Schizophrenia (ScZ) has a strong genetic component with 
a heritability of up to 80% (1,2). Tardive dyskinesia (Td) is 
presented by repetitive and jerking movements in the face, 
neck and tongue and is considered to be a serious side effect 
associated with the use of specific antipsychotic medications 
that are used to treat ScZ and other mental illnesses. Td may 
demonstrate a comorbidity of 20-30% with ScZ (3,4). recent 
studies have reported that complex interactions of genetic, 
environmental and epigenetic factors play important roles in 
ScZ and Td (4-7). dna methylation is an epigenetic mecha-
nism that influences CG dinucleotides by adding a methyl 
group (cH3) to them. Previously, several studies have reported 
the association between dna methylation and ScZ (8-12) and 
Td (13,14). 
insulin resistance has reportedly been associated with 
atherosclerosis and type 2 diabetes (15). The insulin receptor 
substrate 1 (IRS1) gene is located at 2q36.3 (16-18) and it may 
be involved in the regulation of critical metabolic and signaling 
and secretion pathways (19-22). a genome wide association 
study in a French sample showed that one single nucleotide 
polymorphism (SnP) rs2943641, within 500 kb upstream of 
the IRS1 gene, was associated with type 2 diabetes, insulin 
resistance and hyperinsulinemia (23). Furthermore, the IRS1 
gene dna methylation was associated with high body mass 
index (BMi) scores and obesity (24,25). However, there was 
no significant association between the methylation of the IRS1 
gene and type 2 diabetes (26). Gunnell et al (27) attempted 
to evaluate the SnP rs1801278 in the IRS1 gene with ScZ 
but could not identify any significant association. Recently, 
IRS1 gene methylation has been found to be associated with 
ScZ (9,28). Pyrosequencing provides a quantitative analysis 
of dna methylation levels (29-31) and has been employed 
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to detect dna methylation levels of the IRS1 gene in type 2 
diabetes (26) and human islets of type 2 diabetes (32). 
a pilot study using methylated dna immunoprecipitation 
coupled with next-generation sequencing (our unpublished 
data) revealed that the IRS1 gene was hypomethylated in 
Td compared with ScZ groups. The present study aimed 
to quantify dna methylation levels of the IRS1 gene via 
pyrosequencing to examine the association of the IRS1 gene 
dna methylation levels with ScZ or Td. The general linear 
model (GlM) was used to examine the differences in the dna 
methylation levels among diagnostic groups.
Materials and methods
Participants. The present study recruited 10 ScZ patients with 
Td and 10 without Td (nTd) from the Beijing Huilongguan 
Hospital (china) between January 2016 and June 2017. ScZ 
was diagnosed using the diagnostic and Statistical Manual 
of Mental disorders version iV (dSM-iV) (33) and Td was 
confirmed by two well‑trained psychiatrists with extensive 
clinical experiences, based on the criteria of Schooler and 
Kane (34). The 20 ScZ patients were administered with one 
of the following: risperidone, paliperidone or olanzapine. The 
Td patients were typically between 18 and 40 years of age 
and demonstrated an abnormal involuntary movement scale 
(aiMS) score that was >3 in at least one part or >2 in two or 
more parts (35). The same criteria were used for nTd patients 
with aiMS=0. The exclusion criteria included: Patients with 
severe physical or organic encephalopathy, drug or alcohol 
abuse history (except tobacco), pregnant or lactating women, 
patients administered with neurotrophic agents or free radical 
metabolism drugs within 12 weeks prior to participation, and 
other mental illnesses demonstrating a diagnosis of dSM-iV 
axis i (14). The severity of Td symptoms was assessed using 
AIMS, with an inter‑rater correlation coefficient (ICC)>0.80. 
The patients' psychotic symptoms were evaluated using the 
positive and negative syndrome scale (PanSS) (36), with an 
icc>0.85, which was maintained for the PanSS total score 
after the scale training. a total of 10 healthy controls (Hcs) 
matched for age, sex and education were subsequently recruited 
from the local community. ethical approval was received from 
the ethics review Board of Beijing Huilongguan Hospital, 
china, and written informed consent was obtained from all 
participants or their guardians.
DNA extraction, bisulfite treatment and pyrosequencing. 
Fasting venous blood (5 ml) from a forearm vein was obtained 
from each participant at 7:00 a.m. the next morning after 
the day of clinical assessment. dna was extracted from the 
above blood samples using a standard genomic dna sample 
kit (illumina, inc.), according to the manufacturer's protocol. 
dna concentration and purity were detected by nanodrop 
spectrophotometer (nanodrop Technologies, Thermo 
Fisher Scientific, Inc.) and the integrity was tested using 
1% agarose gel electrophoresis (14). Subsequently, 500 ng 
of each sample was treated with bisulfite, by employing the 
Epitect Bisulfite Kit (Qiagen GmbH), according to the manu-
facturer's protocol. Parts of the cpG islands in the promoter 
region within the IRS1 gene were amplified with the help 
of PCR assays. DNA fragments were typically amplified 
using the PyroMark PCR kit (Qiagen GmbH), according 
to the manufacturer's protocol, from 2 µl bisulfite‑treated 
genomic dna. Sample preparation and pyrosequencing 
reactions were subsequently carried out using the PyroMark 
Q96 ID (Qiagen GmbH). The pyrosequencing assays were 
performed for all the study samples on both Pyro Mark Q24 
MDx and PyroMarkQ96 ID, while using Pyro Mark Gold 
reagents (Qiagen GmbH). The Pyro Mark Assay Design 
software version 2.0 (Qiagen GmbH) was used to generate 
the primers for the IRS1, targeting four cpGs in the gene 
promoter (Table i). Percentage of each cpG site and the 
mean methylation percentage of the 4 cpGs quantitatively 
revealed the methylation levels.
Statistical analysis. The χ2 test was used to detect gender 
differences among Td, nTd and Hc groups. Pearson's 
correlation analysis was concurrently used to examine the 
correlations among methylation levels among the 4 cpG 
sites, average level of the 4 cpG sites and severity of ScZ. 
differences among the continuous variables including age 
and education were evaluated by Fisher's F test in the GlM. 
normality of dna methylation levels was tested by the 
Shapiro-Wilk test. differences of dna methylation levels 
among the 3 groups, Td, nTd and Hc, for individual cpG 
sites and the mean of 4 cpGs were detected using GlM. all 
the analyses were performed using SaS version 9.4 software 
(SaS institute, inc.). The Proc PoWer statement in SaS 
was used to compute power in the present study. P<0.05 was 
considered to indicate a statistically significant difference.
Results
Demographics and clinical characteristics. The demographic 
factors in the Td, nTd and Hc groups are presented in 
Table ii. no statistical significances were observed in age 
(P=0.910), sex (P=1.00) and educational levels (P=0.832) 
among the 3 groups. There were no significant differences 
between Td and nTd groups in the disease duration and 
treatment, drug dose quantized using cPZ equivalents or drug 
types. Additionally, no significant difference was observed 
between Td and nTd groups in the PanSS total, positive, 
negative or general scores (Table iii). 
Normality test. The average dna methylation levels of the 4 
cpG sites followed normal distribution (Fig. 1) based on the 
Shapiro-Wilk test (P>0.150). 
Correlation analyses. Table IV demonstrated that no signifi-
cant correlations were found among the individual methylation 
levels of the 4 cpG sites (all P-values >0.05); however, cpG 
sites 1 and 4 demonstrated a strong correlation to the mean 
value of the 4 cpG sites (P<0.0001). Furthermore, there were 
no obvious correlations among cpG sites and the severity of 
ScZ measured by PanSS scores.
GLM analyses. The linear GLM revealed significant differ-
ences with regard to the cpG site 1 and the mean value of the 
4 cpG sites (P=0.0001 and P=0.0126, respectively; Table V 
and Fig. 2), among the 3 groups. Furthermore, the Hc group 
demonstrated higher methylation levels in the cpG site 1 
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compared with those in Td, nTd and Td + nTd (P=0.0003, 
P<0.0001 and P<0.0001, respectively) and the average of 
4 cpG sites (P=0.0176, P=0.0063 and P=0.003, respectively).
Discussion
To the best of our knowledge, this is the first study to 
quantitatively analyze dna methylation using pyrosequencing 
and determine the IRS1 gene promoter methylation levels of 
the 4 cpG sites among the Td, nTd and Hc groups. GlM 
analyses revealed lower methylation levels in cpG site 1 
and the mean value of the 4 cpG sites of the Td, nTd and 
Td + nTd groups compared with the control group.
The methylation status of the IRS1 gene has been 
found to be associated with ScZ through post-mortem 
analysis of human brain tissue from 24 patients with ScZ 
and 24 unaffected controls using the Illumina Infinium 
HumanMethylation450 Bead chip (9). another study 
using blood samples and illumina HumanMethylation450 
Beadchip reported that IRS1 was associated with ScZ (28). 
The present study used pyrosequencing to reveal that the 
dna methylation level in ScZ patients (nTd group) was 
significantly lower compared with healthy controls with 
regard to the cpG site 1 and average values of the 4 cpG 
sites in a chinese sample (Table V). Furthermore, it was 
observed that the TD group demonstrated significantly lower 
Table ii. descriptive characteristics of patients and controls.
Variable  Td group (n=10) nTd group (n=10) Hc group (n=10) P-value
Male/female 5/5 5/5 5/5 1.000
age (years)   31.6±11.8   33.8±11.0   33.2±11.9 0.910
education (years) 10.6±3.2 10.9±2.6 11.4±3.3 0.832
duration of disease (years)   11.1±11.1 10.2±9.2 n/a 1.000
duration of treatment (months)   25.6±22.1   24.5±26.1 n/a 0.570
cPZ equivalents (mg)   662.1±431.4   498.4±275.4 n/a 0.474
drug type    0.584
  1 typical antipsychotic 1 0 n/a 
  1 atypical antipsychotic 6 7 n/a 
  2 atypical antipsychotics 3 3 n/a 
Td, schizophrenia patients with tardive dyskinesia; nTd, schizophrenia patients without tardive dyskinesia; Hc, healthy controls. P-values are 
based on χ2 test for categorical variable and generalized linear model for continuous variable.
Table i. Primer sequences used in the pyrosequencing analysis.
Primer type Primer sequence cpG Sites Position 5'-3'
Forward 5'-aGTGGTTaTaGaGTTTGaTGTTTaTTaGT-3' 4 146-174
reverse 5'-ccTaaaacccaaaaaccTaaaTca-3'  294-271
Sequencing 5'-GTTTGaTGTTTaTTaGTTGTaGTa-3'  158-181
Table iii. clinical parameters of Td and nTd groups.
Variable  Td group (n=10) nTd group (n=10) P-value
PanSS total score   74.0±21.6 73.4±9.7 0.633
PanSS   
  Positive 17.0±7.2 18.7±4.6 0.489
  negative 23.6±8.5 18.4±6.2 0.184
  General 33.6±8.6 35.2±7.0 0.458
abnormal involuntary movement scale 13.4±5.3 0 <0.0001
Td, schizophrenia patients with tardive dyskinesia; nTd, schizophrenia patients without tardive dyskinesia; PanSS, positive and negative 
syndrome scale. P-values are based on t-test.
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dna methylation levels compared with healthy controls 
(Table V). 
 Studies have previously indicated that insulin may act 
as a metabolic signal and the IRS1 gene may influence body 
Figure 2. F-test based on GlM analysis of the average methylation levels of 
4 cpG sites for comparing three groups. Hc, healthy controls; nTd, schizo-
phrenia patients without tardive dyskinesia; Td, schizophrenia patients with 
tardive dyskinesia.
Table IV. Pearson correlation coefficients among methylation levels and clinical characters.
 irS1  irS1 irS1 irS1 irS1    
Variable  Site 1 Site 2 Site 3 Site 4 average PanSST PanSSP PanSSn PanSSG
irS1 Site 1 1.000 -0.345 0.299 0.285 0.821a -0.323 -0.499 -0.219 -0.121
irS1 Site 2  1.000 -0.055 -0.222 -0.276 -0.092 0.013 0.122 0.037
irS1 Site 3   1.000 0.076 0.310 0.198 0.013 0.266 0.111
irS1 Site 4    1.000 0.770a 0.059 -0.052 -0.051 0.153
irS1 average     1.000 -0.160 -0.366 -0.128 0.008
PanSST      1.000 0.521b 0.832a 0.836a
PanSSP       1.000 0.184 0.177
PanSSn        1.000 0.623c
PanSSG         1.000
aP<0.0001, bP <0.05, cP<0.01. irS1, insulin receptor substrate 1; PanSS, positive and negative syndrome scale; PanSST, the total score; 
PanSSP, positive score; PanSn, negative score; PanSSG, general psychopathology score. 
Table V. General linear model analysis of dna methylation levels.
Group Mean/F/t/P-value Site 1 Site 2 Site 3 Site 4 average
Td Mean ± standard deviation 84.3±3.8 100.0±0.0 100.0±0.0 86.9±1.3 92.8±1.0
nTd  84.0±3.4   99.7±0.7   99.8±0.7 86.8±2.9 92.6±1.4
Hc  90.2±1.4   99.8±0.7 100.0±0.0 87.8±5.6 94.4±1.6
Td vs. nTd vs Hc F value 13.14 0.51 0.95 0.14 5.20
 P-value 0.0001 0.6052 0.4011 0.8659 0.0126
Td vs. Hc t value  -4.22 0.92 0.0 -0.42 -2.53
 P-value 0.0003 0.3677 1.0000 0.6758 0.0176
nTd vs. Hc t value -4.59 0.07 -1.20 0.06 -2.97
 P-value <0.0001 0.9433 0.2403 0.9524 0.0063
Td + nTd vs. Hc t value -5.21 0.56 -0.72 -0.54 -3.26
 P-value <0.0001 0.5822 0.4762 0.5903 0.0030
Td vs. nTd t value 0.25 0.85 1.17 -0.50 0.36
 P-value 0.8072 0.4048 0.2527 0.6237 0.7220
Td, schizophrenia patients with tardive dyskinesia; nTd, schizophrenia patients without tardive dyskinesia; Hc, healthy controls. F value is 
based on GlM for comparing three groups and t value is based on GlM for comparing two groups.
Figure 1. normality test for the average methylation level for 4 cpG sites.
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weight control and glucose homeostasis (37-39). Furthermore, 
several studies have also reported associations of IRS1 
polymorphisms with cancer, diabetes, glucose levels and 
obesity (40-44). Furthermore, insulin/insulin receptor 
signaling and the insulin-like growth factor (iGF) pathway 
may have different functions in the central nervous system in 
brain development, blood glucose regulation, dendritic growth 
and neuronal apoptosis (37,45-48). However, che et al (47) 
was unable to identify any association between the IRS1 
gene and epilepsy in a chinese sample but suggested that 
the genes associated with the insulin signaling pathway may 
affect the therapeutic response of temporal lobe epilepsy. 
Previous epidemiologic studies have demonstrated that ScZ 
and other mental illnesses may increase the risk of developing 
type 2 diabetes and other metabolic disorders (49,50). The 
co-morbidity of type 2 diabetes and ScZ may partially be 
due to concurrent biological susceptibility of these two condi-
tions (51,52). as an example, the TCF7L2 gene is associated 
with both type 2 diabetes and type 2 diabetes with ScZ or 
the schizoaffective disorder observed in african american 
patients (50), while the rs7903146 in the TCF7L2 gene is 
associated with ScZ (53). Furthermore, insulin-like growth 
factor ii mrna-binding protein 2 gene (IGF2BP2) may be 
associated with ScZ (54). additionally, insulin signaling, 
among other type 2 diabetes-related pathways, could act as a 
bridge between ScZ and type 2 diabetes (55). However, one 
previous study could not associate rs1801278 in the IRS1 gene 
with ScZ (27). Therefore, the present study provided further 
evidence of the involvement of IRS1 gene with regard to the 
development of ScZ or Td (Table iV).
a previous study examined the dna methylation levels of 
three cpG sites in the IRS1 gene with type 2 diabetes using 
pyrosequencing (26); however, there was no significant differ-
ence in the methylation levels of the 3 cpG sites in the IRS1 
gene between the controls and type 2 diabetes patients, which 
suggested that the dna methylation levels of the IRS1 gene did 
not play a major role in the occurrence of type 2 diabetes (26). 
The present study revealed that both Td and nTd groups had 
significantly lower methylation levels in the CpG site 1 and 
mean values of the 4 cpG sites in the IRS1 gene compared with 
healthy controls (Table V). one primary difference may be that 
there were 3 cpG sites in the above type 2 diabetes study (26), 
while there were 4 in the present study; however, it is possible 
that these cpG sites may be different. notably, the present study 
found numerous similarities, which included the fact that dna 
methylation levels in the diabetes groups were slightly lower 
compared with those in the non‑diabetes groups, specifically 
in the cpG sites 1 and 2 in the entire sample. Furthermore, 
in the above type 2 diabetes study, a similar trend was noted 
among the groups of men and women, despite the fact that the 
differences did not reach a 5% significant level (26).
Previous studies have suggested a role of IRS1 in cogni-
tive impairment and alzheimer's disease (56-59). The present 
study and the previous reports related to the role of IRS1 gene 
methylation in ScZ (9,28) may provide adequate evidence to 
demonstrate that ScZ and alzheimer's disease may share a 
common network of dysregulation (60). Furthermore, epide-
miologic studies have reported a possible association between 
the insulin resistance of type 2 diabetes mellitus and increased 
incidence of alzheimer's disease (61,62). as a matter of fact, 
insulin resistance results in a diminished glucose uptake in 
similar regions of the brain in alzheimer's disease and type 2 
diabetes mellitus (58,59). Therefore, the IRS1 gene may have a 
pleiotropic effect on alzheimer's disease, type 2 diabetes and 
ScZ.
There are a number of strengths in the current study. 
First, this is the first study to conduct a quantitative analysis 
of dna methylation levels of the IRS1 gene in ScZ and Td, 
while previous studies focused on the methylation status 
in ScZ (9,28). Second, the present study applied a GlM to 
examine the methylation levels of the 4 cpG sites within 
the IRS1 gene among Td, nTd and Hc groups. Third, the 
present study tested the normality of the average methyla-
tion levels of the 4 cpG sites and observed that the average 
dna methylation levels of these sites followed normal 
distribution. although correlation analysis was performed, 
significant correlations among the methylation percentages 
of the four cpG sites with the severity of ScZ was not 
observed. However, the present study has certain limitations: 
First, a peripheral blood sample was used in view of the diffi-
culty in obtaining brain tissues to study the disorders of the 
central nervous system. Second, the sample size of the three 
groups in the methylation study was relatively small because 
the prevalence of Td in general population is typically low. 
Based on the Proc PoWer determined in SaS 9.4, the 
power level was 63.3% with 30 individuals on comparing 
overall means in dna methylation levels for the four cpG 
sites; however, it was possible to increase the power up to 
99.1% while testing the cpG site 1. Third, the present study 
examined and included a limited number of sites associated 
with IRS1 gene methylation (only 4 sites), which highlighted 
the importance of increasing the number of sites in future 
investigations. additionally, there may be variations between 
medications, which could not have been detected by the 
present study. 
in conclusion, pyrosequencing demonstrated that the dna 
methylation levels of the IRS1 gene in Td and nTd groups 
were significantly lower compared with the healthy control 
group. However, the dna methylation levels in Td did not 
demonstrate any significant differences compared with those 
in the NTD group. This is the first study to compare CpG 
methylation levels of Td and nTd with healthy controls and 
the findings demonstrated adequate evidence of the possible 
roles of irS1-associated dna methylation in ScZ and Td. in 
the future, it will be worthy to detect age and gender effects 
using a large sample and perform the functional study of these 
4 cpG sites of the IRS1 gene to evaluate the role of this gene in 
the pathogenesis of ScZ and Td.
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